Cannabis and schizophrenia have one of the most complicated relationships in psychiatric medicine. The pharmacological interactions with antipsychotic medications are real but subtle. The behavioural and symptomatic interactions are usually more important. This article focuses on the drug interactions; for the broader story see cannabis and psychosis.
Cannabis interacts with antipsychotics through liver-enzyme induction (especially smoked cannabis on CYP1A2), additive sedation and cognitive impairment, and — most importantly — by worsening positive symptoms and undermining adherence.
The pharmacokinetic layer
Smoked cannabis contains polycyclic aromatic hydrocarbons similar to tobacco smoke. These compounds induce the liver enzyme CYP1A2, which metabolises clozapine and olanzapine. Heavy daily cannabis smoking can lower clozapine and olanzapine levels in a similar way to cigarette smoking — and stopping cannabis abruptly can raise them. The effect of cannabis smoke alone is generally smaller than tobacco's, but in patients who smoke both, the combined induction can be substantial.
THC and CBD themselves can also affect liver enzymes:
- THC is metabolised by CYP2C9 and CYP3A4. It is not a strong inhibitor or inducer at typical recreational doses.
- CBD is a more significant inhibitor of multiple enzymes, including CYP3A4 and CYP2C19, particularly at the high doses used in epilepsy treatment. The Epidiolex (cannabidiol) prescribing information details these interactions.
For most recreational cannabis users, CBD levels are not high enough to cause major interactions, but high-CBD products and CBD oil supplements can. This becomes relevant for antipsychotics metabolised by CYP3A4 — quetiapine, lurasidone, ziprasidone, pimozide, lumateperone — where CBD might modestly raise levels.
The pharmacodynamic layer
Pharmacodynamic interactions are about overlapping effects rather than enzyme metabolism. Cannabis and most antipsychotics both:
- Sedate. Adding cannabis to quetiapine, olanzapine, or clozapine can produce profound sedation, slowed reaction times, and risk of falls.
- Lower blood pressure. Both can cause orthostatic hypotension; combination raises the risk of fainting.
- Affect cognition. Cannabis impairs attention, working memory, and executive function — the same domains many antipsychotics affect modestly. The combination can blunt cognitive function noticeably.
- Affect heart rate. Cannabis often raises heart rate; some antipsychotics can prolong QT. The combination is rarely dangerous in healthy people but warrants caution in those with cardiac risk.
The symptomatic layer — and why it matters most
The most clinically important interaction is not pharmacokinetic. It is that cannabis — particularly high-THC products — worsens psychotic symptoms in people with schizophrenia. NIMH summarises the literature in its substance use and mental health resources. Multiple longitudinal studies and meta-analyses have shown:
- Higher relapse rates in people with schizophrenia who use cannabis
- Earlier age of onset of first episode in users vs non-users
- Worse response to antipsychotic treatment during periods of active use
- Increased risk of rehospitalisation
Modern cannabis is much higher in THC than what was available a generation ago. THC concentrations in flower have roughly tripled since the 1990s, and concentrate products can exceed 80% THC. The relationship between THC potency and psychosis risk is now well documented in studies summarised by groups like the EU-GEI consortium.
What about CBD specifically?
Cannabidiol is being studied as a possible adjunctive antipsychotic in its own right. A 2018 American Journal of Psychiatry trial by McGuire et al. showed modest reductions in positive symptoms with adjunctive CBD compared with placebo. Larger trials are still in progress. Pure pharmaceutical CBD is different from over-the-counter "CBD" products, which often contain unknown amounts of THC, contaminants, or much less CBD than advertised.
If considering CBD, talk to your prescriber. CBD can interact with many medications and should not be combined with antipsychotics without supervision.
You develop worsening voices, paranoia, or disorganised thinking after starting or increasing cannabis use, or new severe sedation and dizziness when combining cannabis with antipsychotics. Call 988 if symptoms are severe.
Practical questions to ask your prescriber or pharmacist
- Does my antipsychotic interact pharmacologically with cannabis?
- If I smoke cannabis daily, should we monitor drug levels?
- If I am thinking of using a CBD supplement, will it interact with my medication?
- What signs should I watch for that cannabis is making my symptoms worse?
- Are there harm-reduction approaches I should know about?
The bottom line
The pharmacological interactions between cannabis and antipsychotics are mostly modest, but the symptomatic effect on schizophrenia is consistent and important. For people who use cannabis, talking openly with a prescriber — without judgement — is the path that produces the best clinical outcomes. Tracking cannabis use alongside symptoms in Frida or another tool can help make the patterns visible and personal, rather than abstract.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.